Workflow
Tokyo Inflation Slows Below Bank of Japan's Target But Rate-Hike Path Seems Intact
WSJ· 2026-02-27 03:03
Inflation in Japan's capital cooled below the central bank's 2% target for the first time in over a year, but the slowdown is unlikely to derail further interest rate hikes. ...
SDM DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Smart Digital Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SDM
TMX Newsfile· 2026-02-27 02:57
Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Smart Digital Group Ltd. (NASDAQ: SDM) between May 5, 2025, and September 26, 2025, of the upcoming lead plaintiff deadline on March 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SDM securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Smart Digital made false and misleading statements and failed to disclose critical information regarding market manipulation and fraudulent promotion schemes [5]. - Specific allegations include the use of offshore accounts for share dumping, omission of risks related to fraudulent trading, and misleading positive statements about the company's business and prospects [5].
Nasdaq And U.S. Index Outlook: Stock Markets Tumble; The Great Tech Fake Out
Seeking Alpha· 2026-02-27 02:55
Group 1 - The article does not provide any relevant content regarding the company or industry [1]
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
TMX Newsfile· 2026-02-27 02:54
Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].
Google Workers Seek ‘Red Lines' on Military A.I., Echoing Anthropic
Nytimes· 2026-02-27 02:53
Core Viewpoint - More than 100 Google A.I. employees have expressed their opposition to the use of Gemini for U.S. surveillance and certain autonomous weapons, highlighting ethical concerns within the company regarding the application of artificial intelligence technology [1] Group 1 - Over 100 employees from Google A.I. have signed a letter directed to Jeff Dean, the chief scientist, indicating their disapproval of Gemini's deployment for surveillance purposes [1] - The letter specifically addresses concerns about the potential use of Gemini in the context of autonomous weapons, raising ethical questions about the technology's implications [1]
Buenaventura Announces Fourth Quarter and Full Year 2025 Results
Businesswire· 2026-02-27 02:51
Core Viewpoint - Compañia de Minas Buenaventura S.A.A. reported its financial results for the fourth quarter and full year of 2025, highlighting its position as Peru's largest publicly-traded precious metals mining company [1] Financial Performance - The company’s results for 4Q25 and FY25 were prepared in accordance with IFRS on a non-GAAP basis and are expressed in U.S. dollars [1]
LSI Industries Prices Public Offering of Common Stock
Businesswire· 2026-02-27 02:50
CINCINNATI--(BUSINESS WIRE)--LSI Industries Inc. (Nasdaq: LYTS, "LSI†or the "Company†) a leading U.S. based manufacturer of commercial lighting and display solutions, announced today that it has priced its previously announced underwritten public offering. The Company is offering 4,600,000 shares of its common stock at a public offering price of $19.75 per share. The gross proceeds to LSI from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to ...
Nvidia Just Crushed Earnings. 1 No-Brainer ETF To Buy Now
The Motley Fool· 2026-02-27 02:45
Nvidia delivered another blowout report, but this could be the best way to take advantage. Nvidia (NVDA 5.55%) delivered another blockbuster earnings report on Wednesday, topping estimates on the top and bottom lines and posting red-hot growth rates. Revenue jumped 73% to $68.1 billion, ahead of the consensus at $66.2 billion. Gross margin improved from 73.4% to 75%, and adjusted net income rose 79% to $39.5 billion, or $1.62 a share, beating expectations at $1.54. No company in history has ever grown this ...
Klarna Hits 9 Million Daily Users as New Bank Features Take Hold
PYMNTS.com· 2026-02-27 02:33
Core Insights - Klarna's app usage has increased by 53% year-over-year, reaching 9 million daily users, indicating a growing integration of its services into everyday financial management [1][2] - The company has doubled its banking customers to 15.8 million in the fourth quarter, reflecting a shift towards more comprehensive financial services beyond just payments [7] - Overall active customers across Klarna's business rose by 28% to 118 million, showcasing strong consumer demand for its offerings [8] Service Expansion - Klarna is evolving its app into a hub for managing money, having recently introduced features such as a debit card, membership tiers, cashback, mobile phone plans, and peer-to-peer payments in Europe [2][9] - The introduction of peer-to-peer payments in 13 European countries is aimed at simplifying money management for users, making transactions quicker and cheaper [9] Company Vision - Klarna's CEO, Sebastian Siemiatkowski, emphasized the company's goal of becoming a global digital bank for the next generation, as evidenced by the increasing daily usage of its app [3][8] - The company aims to save consumers time and money while providing them with greater control over their finances, aligning with its mission to be a reliable everyday money management app [7][8]
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics
ZACKS· 2026-02-27 02:30
Core Insights - Amphastar Pharmaceuticals reported a revenue of $183.11 million for the quarter ended December 2025, reflecting a year-over-year decline of 1.8% and an EPS of $0.73, down from $0.92 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $194.03 million by 5.63%, while the EPS was 24.49% below the consensus estimate of $0.97 [1] Revenue Performance - BAQSIMI generated net revenues of $46.71 million, which is 11.8% higher year-over-year but below the average estimate of $52.07 million from two analysts [4] - Primatene MIST reported net revenues of $27.93 million, a decrease of 3.5% compared to the previous year and below the estimated $31.48 million [4] - Lidocaine achieved net revenues of $14.9 million, exceeding the estimate of $13.51 million and showing a year-over-year increase of 3.5% [4] - Epinephrine's net revenues were $17.09 million, down 8.6% year-over-year and below the average estimate of $19.78 million [4] - Glucagon reported net revenues of $14.08 million, significantly higher than the estimated $10.59 million, but this represents a drastic year-over-year decline of 45% [4] Stock Performance - Amphastar's shares have returned +7.1% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +0.6% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]